Malakoplakia of the Gastrointestinal Tract JOHN MCCLURE B.Sc., M.D., M.R.C.Path., D.M.J.Path
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
USMLE – What's It
Purpose of this handout Congratulations on making it to Year 2 of medical school! You are that much closer to having your Doctor of Medicine degree. If you want to PRACTICE medicine, however, you have to be licensed, and in order to be licensed you must first pass all four United States Medical Licensing Exams. This book is intended as a starting point in your preparation for getting past the first hurdle, Step 1. It contains study tips, suggestions, resources, and advice. Please remember, however, that no single approach to studying is right for everyone. USMLE – What is it for? In order to become a licensed physician in the United States, individuals must pass a series of examinations conducted by the National Board of Medical Examiners (NBME). These examinations are the United States Medical Licensing Examinations, or USMLE. Currently there are four separate exams which must be passed in order to be eligible for medical licensure: Step 1, usually taken after the completion of the second year of medical school; Step 2 Clinical Knowledge (CK), this is usually taken by December 31st of Year 4 Step 2 Clinical Skills (CS), this is usually be taken by December 31st of Year 4 Step 3, typically taken during the first (intern) year of post graduate training. Requirements other than passing all of the above mentioned steps for licensure in each state are set by each state’s medical licensing board. For example, each state board determines the maximum number of times that a person may take each Step exam and still remain eligible for licensure. -
Non-Commercial Use Only
Veins and Lymphatics 2012; volume 1:e6 Ulcerated hemosiderinic three months previous to this therapy. Significant improvement in these injuries, Correspondence: Eugenio Brizzio and Alberto dyschromia and iron deposits with a reduction in the dimensions of the Lazarowski, San Martín 965, 1st floor (Zip code within lower limbs treated brown spot (9 of 9) at Day 90, and complete 1004) Buenos Aires, Argentina. with a topical application scarring with a closure time ranging from 15 Tel. +54.11.4311.5559. to 180 days (7 of 9) were observed. The use of E-mail: [email protected]; of biological chelator [email protected]; topical lactoferrin is a non-invasive therapeu- [email protected]; tic tool that favors clearance of hemosiderinic 1 2 [email protected] Eugenio Brizzio, Marcelo Castro, dyschromia and scarring of the ulcer. The 3 2 Marina Narbaitz, Natalia Borda, success of this study was not influenced Key words: ulcerated haemosiderinic dyschro- Claudio Carbia,2 Laura Correa,4 either by the hemochromatosis genetics or mia, liposomal Lactoferrin, scarring, hemo- Roberto Mengarelli,5 Amalia Merelli,2 the iron metabolism profile observed. siderin-ferritin. Valeria Brizzio,2 Maria Sosa,6 Acknowledgments: the authors would like to Biagio Biancardi,7 Alberto Lazarowski2 thank P. Girimonte for her assistance with the statistical analysis of the results. We also wish to Introduction thank the patients who made this study possible. 1International Group of Compression and Conference presentation: part of the present Argentina Medical Association, Buenos Chronic venous insufficiency (CVI) is one of study has been presented at the following con- 2 Aires, Argentina; Department of Clinical the most significant health problems in devel- gresses: i) XX Argentine Congress of Hematology, Biochemistry, Institute of oped countries. -
WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA). -
Simple Technique to Identify Haemosiderin in Immunoperoxidase Stained Sections
J Clin Pathol: first published as 10.1136/jcp.37.10.1190 on 1 October 1984. Downloaded from 1190 Technical methods Phosphate buffer at pH 8*0 gave the sharpest 2 Rozenszajn L, Leibovich M, Shoham D, Epstein J. The esterase staining reactions, although there was little differ- activity in megaloblasts, leukaemic and normal haemopoietic cells. Br J Haematol 1968; 14:605-19. ence at pH 7-0 or pH 7-5. As the buffer pH was 3Hayhoe FGJ, Quaglino D. Haematological cytochemistry. Edin- increased above pH 8-0 staining with both substrates burgh: Churchill Livingstone, 1980. became progressively weaker, especially above pH 4Li CY, Lam KW, Yam LT. Esterases in human leucocytes. J 9.0. Below pH 7-0 staining with a-naphthyl butyrate Histochem Cytochem 1973;21:1-12. Yam LT, Li CY, Crosby WH. Cytochemical identification of became weaker, and below pH 5*0 staining with monocytes and granulocytes. Am J Clin Pathol 1971;55:283- naphthol AS-D chloroacetate began to disappear. 90. 6 Armitage RJ, Linch DC, Worman CP, Cawley JC. The morphol- This work was supported by a Medical Research ogy and cytochemistry of human T-cell subpopulations defined by monoclonal antibodies and Fc receptors. Br J Haematol Council project grant. I thank Professor FGJ 1983;51:605-13. Hayhoe for valuable advice. References Requests for reprints to: Dr DM Swirsky, Department of Gomori G. Chloroacyl esters as histochemical substrates. J His- Haematological Medicine, University Clinical School, Hills tochem Cytochem 1953;1:469-70. Road, Cambridge CB2 2QL, England. Simple technique to identify identification of the two compounds on the same haemosiderin in slide. -
| Oa Tai Ei Rama Telut Literatur
|OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn . -
Gomori Prussian Blue Iron Stain Histology Staining Procedure
2505 Parview Road ● Middleton, WI 53562-2579 ● 800-383-7799 ● www.newcomersupply.com ● [email protected] July 2016 Gomori Prussian Blue Iron Stain - Technical Memo SOLUTIONS: 500 ml 1 Liter Hydrochloric Acid 20%, Aqueous Part 12087A Part 12087B Potassium Ferrocyanide 10%, Aqueous Part 13392A Additionally Needed: Iron Control Slides Part 4320 or Iron, Animal Control Slides Part 4321 Xylene, ACS Part 1445 Alcohol, Ethyl Denatured, 100% Part 10841 Alcohol, Ethyl Denatured, 95% Part 10842 Nuclear Fast Red Stain, Kernechtrot Part 1255 Hydrochloric Acid 5%, Aqueous Part 12086 (for acid cleaning glassware) For storage requirements and expiration date refer to individual product labels. APPLICATION: PROCEDURE NOTES: Newcomer Supply Gomori Prussian Blue Iron Stain is used to detect 1. Acid clean all glassware/plasticware (12086) and rinse thoroughly loosely bound ferric iron in tissue sections, bone marrow smears and in several changes of distilled water. Cleaning glassware with blood smears. This histochemical reaction is sensitive enough to bleach is not equivalent to acid washing. demonstrate even minute amounts of iron deposits in blood cells, bone 2. Drain staining rack/slides after each step to prevent solution carry marrow, spleen and liver. over. 3. Do not allow sections to dry out at any point during staining METHOD: procedure. Fixation: Formalin 10%, Phosphate Buffered (Part 1090) 4. Wash well after Nuclear Fast Red Stain, Kernechtrot to avoid a. Chromate fixatives should be avoided cloudiness in dehydration steps. b. Fix smears per laboratory protocol 5. If using a xylene substitute, closely follow the manufacturer’s Technique: Paraffin sections cut at 5 microns or prepared smears recommendations for deparaffinization and clearing steps Solutions: All solutions are manufactured by Newcomer Supply, Inc. -
Pelvic Malakoplakia Presenting As Endometrial Cancer: a Case Report
Case report Obstet Gynecol Sci 2020;63(4):538-542 https://doi.org/10.5468/ogs.19245 pISSN 2287-8572 · eISSN 2287-8580 Pelvic malakoplakia presenting as endometrial cancer: a case report Jeong Soo Cho, MD, Hye In Kim, MD, Jung Yun Lee, MD, Eun Ji Nam, MD, Sunghoon Kim, MD, Young Tae Kim, MD, Sang Wun Kim, MD, PhD Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea Malakoplakia is a rare granulomatous, inflammatory disease generally manifesting as ulcers of the urogenital tract, especially in the bladder, but it can occur in any part of the body. Because of its varied clinical presentations, malakoplakia is considered for differential diagnosis upon suspicion. The final diagnosis is confirmed by the presence of Michaelis-Gutmann bodies. We report a case of pelvic malakoplakia accompanied by left lower quadrant pain that was misdiagnosed as endometrial cancer with pelvic mass based on imaging studies. The patient underwent dilatation and curettage, and the pathology report revealed no malignancy. Because of persistent pain and septic shock, she underwent a debulking operation to remove the mass. Histopathologic examination revealed malakoplakia. For postoperative management, she received broad-spectrum antibiotics, but abdominal pelvic computerized tomography performed on postoperative day 9 revealed pelvic mass recurrence. To the best of our knowledge, this is the only rare case report of pelvic malakoplakia mimicking endometrial cancer. Keywords: Malakoplakia; Endometrial cancer; Pelvic inflammatory disease; Menopause Introduction We present a case which was first suspected as a severe infection involving left ovary and salpinx and as endometrial Malakoplakia was first announced by Michaelis and Gut- cancer later. -
Detection of Acute TLR-7 Agonist-Induced Hemorrhagic Myocarditis in Mice by Refined Multi-Parametric Quantitative Cardiac MRI
bioRxiv preprint doi: https://doi.org/10.1101/502237; this version posted December 21, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. CMR imaging for hemorrhagic myocarditis in mice Baxan et al. 2018 Detection of acute TLR-7 agonist-induced hemorrhagic myocarditis in mice by refined multi-parametric quantitative cardiac MRI. Nicoleta Baxan1, Angelos Papanikolaou2, Isabelle Salles-Crawley2, Amrit Lota3, Rasheda Chowdhury2, Olivier Dubois1, Jane Branca4, Muneer G. Hasham4, Nadia Rosenthal2,4, Sanjay K. Prasad3, Lan Zhao1,2, Sian E. Harding2, Susanne Sattler2 Affiliations: 1Biological Imaging Centre, Department of Medicine, Imperial College London, London, 2National Heart and Lung Institute, Imperial College London, London, W12 0NN, UK 3Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London SW3 6NP, UK 4The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA Abstract BACKGROUND: Hemorrhagic myocarditis is a potentially fatal complication of excessive levels of systemic inflammation. It has been reported in viral infection, but is also possible in systemic autoimmunity. Cardiac magnetic resonance (CMR) imaging is the current gold standard for non-invasive detection of suspected inflammatory damage to the heart and changes in T1 and T2 relaxation times are commonly used to detect edema associated with immune cell infiltration and fibrosis. These measurements also form the basis of the Lake Louise Criteria, which define a framework for the CMR-based diagnosis of myocarditis. However, they do not take into account the possibility of hemorrhage leading to tissue iron deposition which strongly influences T1 and T2 measurements and may complicate interpretation based on these two parameters only. -
Supporting Information
Supporting Information Salazar et al. 10.1073/pnas.0804373105 SI Materials and Methods and postfixed for 24 h (4% paraformaldehyde and 0.1 M PBS). Chemicals and Antibodies. MPTP hydrochloride, 6-hydroxydopa- Alternatively, for TH cell counting in hemimesencephali, brains mine hydrobromide, Chelex 100, and D-amphetamine sulfate were postfixed for 48 h. Next, fixed brains were cryopreserved in were purchased from Sigma. Peptide N-glycosidase (PNGase) F 30% sucrose and cut on a freezing Microtome. Free-floating was purchased from New England Biolabs. DMT1 antibodies, sections were permeabilized, blocked for nonspecific binding previously developed and characterized (1), were used to rec- sites, and incubated with primary antibodies. Immunolabeling ognize the ϩIRE C-terminal region, the ϪIRE C-terminal was visualized using Alexa 488- and Cy3-conjugated secondary region, the 4th extracellular domain (Alpha Diagnostics), and antibodies (Invitrogen and Jackson ImmunoResearch, respec- the 3rd extracellular domain (Biosonda). In addition, the fol- tively) or HRP-conjugated secondary antibodies and DAB rev- lowing antibodies were used: rabbit anti-TH (Pel-Freez Biologi- elation (Vector Laboratories). cals), mouse anti-TH (Diasorin), rat anti-CD11b/Mac1 (Sero- tec), and mouse anti-actin (Sigma). Animals. Male C57BL/6J mice 12 weeks old were obtained from Janvier Breeding Center. Microcytic mice (MK/ReJ-mk/ϩ) were Tissue Preparation for Iron Measurement and Western Blot Analysis. obtained from Funmei Yang, University of Texas Health Sci- Within2hafterautopsy, the brains were dissected and blocks of ences Center, San Antonio, TX, and Mark Fleming, Harvard hemibrainstem were frozen in dry ice and stored at Ϫ80 °C. University School of Medicine, Boston, MA, and subsequently Serial 20-m-thick sections were cut from the frozen blocks at maintained as an inbred stock by breeding heterozygotes in a Ϫ12 °C by using a cryostat, thaw-mounted onto gelatin/ 129sv background. -
A Clinicopathological Classification of Granulomatous Disorders
Postgrad Med J 2000;76:457–465 457 Postgrad Med J: first published as 10.1136/pmj.76.898.457 on 1 August 2000. Downloaded from REVIEWS A clinicopathological classification of granulomatous disorders D Geraint James Abstract Granulomatous disorders comprise a large Granulomatous disorders comprise a family sharing the common histological de- large family sharing the histological de- nominator of granuloma formation. Granulo- nominator of granuloma formation. A mas may be confluent or discrete; the degree of granuloma is a focal compact collection of necrosis is variable; the cell components diVer; inflammatory cells, mononuclear cells and the presence or absence of Schaumann predominating, usually as a result of the bodies and of calcification are distinctive. A persistence of a non-degradable product clinicopathological synthesis provides the most and of active cell mediated hypersensitiv- secure foundation. ity. There is a complex interplay between invading organism or prolonged antige- Granuloma formation naemia, macrophage activity, a Th1 cell A granuloma is a focal, compact collection of response, B cell overactivity and a vast inflammatory cells, mononuclear cells pre- array of biological mediators. DiVerential dominating; it is usually formed as a result of the persistence of a non-degradable product of diagnosis and management demand a active hypersensitivity. The granuloma is the Royal Free Hospital skilful interpretation of clinical findings end result of a complex interplay between School of Medicine, and pathological evidence. They are clas- University of London, invading organism or antigen, chemical, drug sified into infections, vasculitis, immuno- Rowland Hill Street, or other irritant, prolonged antigenaemia, London NW3 2PF, UK logical aberration, leucocyte oxidase macrophage activity, a Th1 cell response, B cell deficiency, hypersensitivity, chemicals, Correspondence to: overactivity, circulating immune complexes, Professor James and neoplasia. -
Malakoplakia of the Liver in a Patient with Acquired Immunodeficiency
Tzu Chi Medical Journal 23 (2011) 103e104 Contents lists available at ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Case Report Malakoplakia of the liver in a patient with acquired immunodeficiency syndrome Jun-Yi Sim, Yung-Hsiang Hsu* Department of Pathology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan article info abstract Article history: Malakoplakia, a rare chronic granulomatous disease that often associates with immunosuppression or Received 16 February 2011 immunodeficiency, has been reported to affect many organs, mainly in the genitourinary tract. Herein, Received in revised form we report a case of malakoplakia of the liver in a 44-year-old man with acquired immunodeficiency 16 March 2011 syndrome who was poorly compliant with highly active antiretroviral therapy and subsequently died of Accepted 28 March 2011 multiple systemic infections. Malakoplakia of the liver was observed incidentally on autopsy. Copyright Ó 2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. Key words: All rights reserved. AIDS Liver Malakoplakia 1. Introduction admitted in March and June 2004 for chronic watery diarrhea, and a stool acid-fast stain was positive for cryptosporidium. Syphilis Malakoplakia is a chronic granulomatous disease caused by an was confirmed by serologic test for syphilis/rapid plasma reagin abnormal inflammatory response to infection that is usually (þ)andTreponema pallidum haemagglutination (þ). Genital described in immunosuppressed or immunodeficient patients. It is herpes and warts were noted. The patient was discharged after most commonly seen in the urinary bladder, although it has been symptoms were controlled with antibiotics and antifungal reported in other locations, including the testis, prostate, epidid- prophylactics. -
Malakoplakia of the Testis
Surgical Science, 2014, 5, 233-235 Published Online May 2014 in SciRes. http://www.scirp.org/journal/ss http://dx.doi.org/10.4236/ss.2014.55040 Malakoplakia of the Testis Siddharth P. Dubhashi1*, Harsh Kumar2, Vivek Kulkarni1, Adil M. Suleman1 1Department of General Surgery, Padmashree Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, India 2Department of Pathology, Padmashree Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, India Email: *[email protected] Received 4 April 2014; revised 3 May 2014; accepted 10 May 2014 Copyright © 2014 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Malakoplakia is an uncommon chronic inflammatory disease usually affecting the urogenital tract and often associated with the infection due to E. coli. It is characterised by the presence of Von Hansemann cells and intracytoplasmic inclusion bodies called Michaelis-Gutmann Bodies. Testes are affected in 12% cases. The lesion mainly occurs in middle aged men, appearing clinically as epididymo-orchitis or testicular enlargement with fibrous consistency and some soft areas. Or- chidectomy is the only way to differentiate the lesion from other malignant or infected processes. This is a case report of a young patient with testicular malakoplakia. Keywords Michaelis-Gutmann Bodies, Plaques, Testicular Malakoplakia, Von-Hansemann Cells 1. Introduction Malakoplakia is an uncommon chronic inflammatory disease usually affecting the urogenital tract and often as- sociated with the infection due to E. coli [1]. The condition was originally described by Michaelis and Gutmann in1902 [2].